Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair

This study was a target trial emulation using the National Health Claims database established by the Korean National Health Insurance Service (K-NHIS). 8,325 patients were included.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Abdominal Aortic Aneurysms (AAA) Aneurysm Aortic Aneurysm Aortic Aneurysm, Abdominal Aortic Diseases Cardiovascular Diseases Endovascular Aneurysm Repair (EVAR) Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Among these patients, any patients who were prescribed SAPT or DAPT at the date of discharge from the index hospitalization for standard EVAR were defined as being in the SAPT group (N=4,162) and the DAPT group (N=4,163), respectively.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients who underwent EVAR for AAA and were successfully discharged

Exclusion criteria

Patients who had experienced a myocardial infarction
Patients who had experienced a stroke
Patients who had experienced percutaneous coronary intervention
Patients who had history of peripheral disease
Patients who had major bleeding event within 1 year of admission
Those prescribed non-vitamin K antagonist oral anticoagulant or warfarin
Patients who did not prescribe any antiplatelet therapy

Treatment and study plan

Primary outcomes

Major adverse cardiac and cerebrovascular events (MACCE)

Time frame: 1 year after EVAR

composite of all-cause death, myocardial infarction (MI), or ischemic stroke
Major or clinically relevant non-major bleeding

Time frame: 1 year after EVAR

Diagnostic codes in the primary or secondary position and transfusion receipt
Re-intervention or surgery for AAAs

Time frame: 1 year after EVAR

Re-intervention or surgery for AAAs

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Official study title

A Target Trial Emulation for Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair

Acronym: EVAR_DAPT_SAPT

Important dates

Study start: 2003
Primary completion: 2023
Study completion: 2023
First posted: Mar 14, 2025
Registry last updated: Mar 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed